Molecular Diagnostics in Hemostatic Disorders
Section snippets
Molecular testing for inherited thrombophilia
A predisposition to thrombosis, or thrombophilia, may be genetically predetermined based on overexpression of procoagulant proteins or underexpression of anticoagulant proteins. Thrombophilia is termed acquired when it is associated with external risk factors for thrombosis, including oral contraceptive or estrogen therapy, pregnancy or postpartum state, antiphospholipid syndrome, cancer, chemotherapy, and so forth. Major anticoagulant proteins include PC, AT, and PS. The serine protease
Indications for genetic testing of hemostatic disorders
The clinical indications for genetic testing in coagulation disorders are constantly evolving. Professional organizations have made recommendations for such testing in thrombotic disease. There is general agreement that a DNA-based assay for the FVL and PT gene mutations is indicated in the following circumstances: (1) venous thromboembolism (VTE) at an age younger than 50 years, (2) recurrent VTE, (3) VTE when occurring at an unusual site, (4) unprovoked VTE, (5) VTE in patient with a family
Strengths of molecular testing for hemostatic disease
Molecular testing is extremely useful for resolving patients as heterozygous or homozygous for a particular mutation associated with a coagulation disorder. Because clot-based assays have relatively wide analytic variability and carrier levels may overlap the “normal” ranges, this cannot be reliably done by assays based on factor levels. In addition, activity levels of homozygotes and heterozygotes may overlap. Other difficulties with factor assays, activity-based and antigenic, are that test
Practical issues in molecular hemostasis testing
Pathology laboratories that perform molecular diagnostic testing for coagulation disorders are faced with the same practical and ethical issues that are encountered in other types of genetic testing.26 Informed consent is typically required for all genetic testing. A recognized exception includes FVL testing; the American College of Medical Genetics (ACMG) recommends that formal informed consent not be required for FVL testing and that laboratories assume that informal consent was obtained.21
Pharmacogenomics in treating thrombosis: molecular testing for “personalized” Coumadin dosing
One purpose of “personalized medicine” is to identify genetic differences that affect the metabolism or action of a drug. Ideally, these differences would be detected before prescribing a medication, allowing drug doses to be tailored to an individual's genetic composition. One such example is using cytochrome P450 (2C9) and vitamin K epoxide reductase (VKORC1) genotyping to select a warfarin dose. Warfarin has a narrow therapeutic range, and adverse drug reactions are common.31 Drug
Hemophilia A
Hemophilia A (HA) is a well-characterized X-linked recessive bleeding disorder resulting from deficient or defective factor VIII (F8) protein. Clinical disease severity correlates with residual F8 activity, ranging from less than 1% for severe, 1% to 5% for moderate, and 5% to 40% (IU/dL) for mild HA. Most carriers of an HA mutation have F8 levels of greater than 35%; thus, they may not be detected by F8 activity assays that have wide reference ranges (∼50%–150%). Only approximately 10% of
Hemophilia B
Hemophilia B (HB) is an X-linked recessive bleeding disorder caused by a deficiency of coagulation factor IX (F9). The F9 gene is located on Xq27.1 to Xq27.2 and contains eight exons. The HB bleeding disorder is clinically indistinguishable from HA. A database encompassing known mutations in the F9 gene is also available.73 Notable entries include several promoter mutations (HB Leyden 1, 2, 3) that are associated with a phenotype characterized by severe disease at birth and significant
von Willebrand disease
The most commonly diagnosed inherited bleeding disorder, vWD, is caused by a qualitative or quantitative abnormality of the von Willebrand factor (vWF), a multimeric glycoprotein that plays a critical role in primary hemostasis and serves as a protective carrier protein for F8. After binding to the platelet glycoprotein Ib receptor, vWF forms a bridge between the platelet surface and subendothelial collagen exposed by vascular injury. vWF consists of low, intermediate, and high molecular weight
Genomics and proteomics in hemostasis
The information gleaned from the Human Genome Project has not yet translated into a better understanding of the hemostatic system at the molecular level. Presumably, a detailed human genetic map would facilitate discovery of new genetic markers of bleeding and thrombophilia. Such knowledge could then be used more precisely to estimate hemostatic risk and to refine treatment of coagulation disorders.84 Mutations in regions that are not routinely assessed, such as deep intronic portions of genes,
Future of genetic testing in hemostasis
As knowledge of the human genome expands, layers of complexity beyond DNA and RNA sequences may be defined to the point at which analysis is useful in a clinical context. Epigenetic factors (changes in the genome that do not involve alterations in the DNA sequence, per se [eg, methylation of bases, modifications of proteins associated with the DNA]) and expression of microRNAs (short single-stranded regulatory RNA molecules) may prove useful in thrombophilia diagnostics. Furthermore, mutations
References (97)
Advances in understanding pathogenic mechanisms of thrombophilic disorders
Blood
(2008)- et al.
Heerlen polymorphism of protein S, an immunologic polymorphism due to dimorphism of residue 460
Blood
(1990) - et al.
Deficient APC-cofactor activity of protein S Heerlen in degradation of factor Va Leiden: a possible mechanism of synergism between thrombophilic risk factors
Blood
(2000) - et al.
Rapid detection of the prothrombin C20209T variant by differential sensitivity to restriction endonuclease digestion
J Thromb Haemost
(2003) - et al.
High resolution melting applications for clinical laboratory medicine
Exp Mol Pathol
(2008) - et al.
Unlabeled oligonucleotides as internal temperature controls for genotyping by amplicon melting
J Mol Diagn
(2007) - et al.
American College of Medical Genetics consensus statement on factor V Leiden mutation testing
Genet Med
(2001) - et al.
The largest prospective warfarin-treated cohort supports genetic forecasting
Blood
(2009) - et al.
Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications
Lancet
(1999) - et al.
The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen
Blood
(2005)
Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin
Genet Med
Executive summary: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition)
Chest
Recurrent inversion breaking intron 1 of the factor VIII gene is a frequent cause of severe hemophilia A
Blood
Mutations in the ER-Golgi intermediate compartment protein ERGIC-53 cause combined deficiency of coagulation factors V and VIII
Cell
Molecular analysis of the ERGIC-53 gene in 35 families with combined factor V-factor VIII deficiency
Blood
Evaluation of DHPLC in the analysis of hemophilia A
J Biochem Biophys Methods
Somatic mosaicism in hemophilia A: a fairly common event
Am J Hum Genet
Two novel point mutations correlate with an altered developmental expression of blood coagulation factor IX (hemophilia B Leyden phenotype)
Blood
Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor
J Thromb Haemost
Genetic linkage and association analysis in type 1 von Willebrand disease: results from the Canadian type 1 VWD study
J Thromb Haemost
Linkage analysis in families diagnosed with type 1 von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 VWD
J Thromb Haemost
Effect of von Willebrand disease type 2B and type 2M mutations on the susceptibility of von Willebrand factor to ADAMTS-13
J Thromb Haemost
Transcript profiling of human platelets using microarray and serial analysis of gene expression
Blood
Integration of proteomics and genomics in platelets: a profile of platelet proteins and platelet-specific genes
Mol Cell Proteomics
Gene profiling identifies secreted protein transcripts from peripheral blood cells in coronary artery disease
J Mol Cell Cardiol
Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions
Blood
Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects
Blood
Cloning and expression of the cDNA for human antithrombin III
Nucleic Acids Res
The structure and evolution of a 461 amino acid human protein C precursor and its messenger RNA, based upon the DNA sequence of cloned human liver cDNAs
Nucleic Acids Res
Isolation and sequence of the cDNA for human protein S, a regulator of blood coagulation
Proc Natl Acad Sci U S A
Increased efficiency of mRNA 3′ end formation: a new genetic mechanism contributing to hereditary thrombophilia
Nat Genet
Rapid detection of the prothrombin C20209T transition by Light Cycler analysis
Thromb Haemost
Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C
Proc Natl Acad Sci U S A
Mutation in blood coagulation factor V associated with resistance to activated protein C
Nature
Association for Molecular Pathology
Mutation scanning of the RET protooncogene using high-resolution melting analysis
Clin Chem
Unlabeled oligonucleotide probes modified with locked nucleic acids for improved mismatch discrimination in genotyping by melting analysis
Biotechniques
Masking selected sequence variation by incorporating mismatches into melting analysis probes
Hum Mutat
Expanded instrument comparison of amplicon DNA melting analysis for mutation scanning and genotyping
Clin Chem
Rapid and sensitive detection of BRCA1/2 mutations in a diagnostic setting: comparison of two high-resolution melting platforms
Clin Chem
Discovering rare variants by use of melting temperature shifts seen in melting curve analysis
Clin Chem
Laboratory evaluation of hypercoagulability with venous or arterial thrombosis
Arch Pathol Lab Med
Testing for hereditary thrombophilia: a retrospective analysis of testing referred to a national laboratory
BMC Clin Pathol
Does thrombophilia testing help in the clinical management of patients?
Br J Haematol
Prevalence of factor V 1691 G-A (Leiden) and prothrombin G20210A polymorphisms and the risk of venous thrombosis among cancer patients
J Thromb Thrombolysis
What does “a gene for heart disease” mean? A focus group study of public understandings of genetic risk factors
Am J Med Genet A
American College of Medical Genetics
Points to consider: ethical, legal, and psychosocial implications of genetic testing in children and adolescents. American Society of Human Genetics Board of Directors, American College of Medical Genetics Board of Directors
Am J Hum Genet
Cited by (4)
Pediatric bleeding disorders
2021, Biochemical and Molecular Basis of Pediatric DiseaseHemostasis and coagulation instrumentation
2019, Rodak’s Hematology: Clinical Principles and ApplicationsGenetic and Molecular Testing in Thrombosis and Hemostasis: Informing Surveillance, Treatment, and Prognosis
2019, Seminars in Thrombosis and Hemostasis